Table 1 Antiproliferation properties of the tested compounds.

17a

7.971 ± 0.338 (2.1)

12.920 ± 0.559 (1.3)

5.857 ± 0.259 (2.9)

14.450 ± 0.259 (1.2)

17b

7.409 ± 0.228 (3.1)

12.230 ± 0.297 (1.9)

5.826 ± 0.213 (4.0)

10.990 ± 0.135 (2.1)

17c

6.317 ± 0.132 (2.2)

9.148 ± 0.154 (1.5)

5.269 ± 0.172 (2.6)

12.540 ± 0.205 (1.1)

17d

9.278 ± 0.084 (1.9)

15.570 ± 0.329 (1.2)

5.782 ± 0.130 (3.1)

14.590 ± 0.270 (1.2)

17e

6.989 ± 0.101 (2.4)

9.479 ± 0.278 (1.8)

5.640 ± 0.273 (2.9)

7.727 ± 0.155 (2.1)

17f

3.716 ± 0.099 (10.7)

5.252 ± 0.224 (7.6)

5.289 ± 0.175 (7.5)

 > 50.000 ± 2.111 (< 0.8)

17g

5.006 ± 0.364 (3.8)

6.092 ± 0.132 (3.1)

5.426 ± 0.152 (3.5)

8.149 ± 0.277 (2.3)

17h

3.080 ± 0.165 (2.6)

6.354 ± 0.170 (1.3)

4.067 ± 0.054 (2.0)

4.149 ± 0.288 (2.0)

17i

4.142 ± 0.042 (> 12.1)

13.450 ± 0.898 (> 3.7)

4.808 ± 0.148 (> 10.4)

 > 50.000 ± 1.431 (–)

17j

3.487 ± 0.033 (> 14.3)

6.930 ± 0.337 (> 7.2)

3.874 ± 0.102 (> 12.9)

6.059 ± 0.157 (> 8.3)

17k

3.281 ± 0.022 (2.5)

6.659 ± 0.095 (1.2)

4.978 ± 0.095 (1.6)

6.467 ± 0.385 (1.3)

17l

4.162 ± 0.129 (1.9)

6.151 ± 0.413 (1.3)

4.852 ± 0.082 (1.6)

7.281 ± 0.316 (1.1)

17m

3.438 ± 0.083 (2.8)

5.605 ± 0.063 (1.7)

4.210 ± 0.085 (2.3)

8.182 ± 0.435 (1.2)

17n

5.095 ± 0.191 (> 9.8)

15.340 ± 0.911 (> 3.3)

4.368 ± 0.156 (> 11.5)

 > 50.000 ± 1.752 (–)

17o

3.756 ± 0.064 (> 13.3)

6.273 ± 0.148 (> 8.0)

4.666 ± 0.086 (> 10.7)

36.000 ± 1.150 (> 1.3)

17p

5.512 ± 0.138 (2.6)

7.316 ± 0.226 (1.9)

5.430 ± 0.140 (2.6)

12.990 ± 0.284 (1.1)

17q

11.760 ± 0.400 (2.3)

13.360 ± 0.325 (2.0)

9.134 ± 0.314 (3.0)

24.510 ± 0.204 (1.1)

17r

7.670 ± 0.379 (2.2)

8.292 ± 0.497 (2.1)

6.224 ± 0.082 (2.7)

14.180 ± 0.135 (1.2)

17s

5.416 ± 0.288 (1.9)

6.134 ± 0.131 (1.7)

4.639 ± 0.068 (2.2)

8.096 ± 0.091 (1.3)

17t

7.342 ± 0.161 (3.5)

9.474 ± 0.097 (2.7)

6.447 ± 0.111 (3.9)

14.120 ± 0.201 (1.8)

Sunitinib^b

9.67

16.91

3.97

–

5-Fluorouracil^b,c

20.43

–

3.15

–

Doxorubicin^c

–

–

–

5.93